Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.

ABSTRACT:

Objective

Dabigatran was the first of a new generation of anticoagulation drugs for the indication of non-valvular atrial fibrillation (AF) to be approved. Evidence show that dabigatran 150 mg twice daily significantly reduces the risk of stroke and systemic embolism (RR = 0.65; p < 0.001) and shows a comparable rate of major bleedings (RR = 0.93; p = 0.32), whereas dabigatran 110 mg twice daily was associated with a comparable rate of stroke and systemic embolism (RR = 0.90; p = 0.30) and a significantly lower rate of major bleedings compared to warfarin treatment (RR = 0.80; p = 0.003). The purpose is to review current economic evaluations of these alternatives for healthcare professionals to include these findings in their decision-making.

Methods

A systematic literature

SUBMITTER: Hesselbjerg LJ 

PROVIDER: S-EPMC4627374 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature